Board of Directors

Ameet Mallik

Non-Executive Chairman

Mr. Mallik has served as Rafael Holdings’ ( NYSE:RFL) Chief Executive Officer since May 1, 2021. Mr. Mallik served as Executive Vice President and Head, U.S. Oncology of Novartis from November 2017 through April 2021. In this role, Mr. Mallik was responsible for Novartis’s commercial and medical oncology operations in the United States. From November 2015 to November 2017, Mr. Mallik served as Global Head, Marketing, Value and Access, and from April 2014 to November 2015 as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Head of Biopharmaceuticals & Oncology Injectables at Sandoz. Mr. Mallik previously worked as an Associate Principal at McKinsey and Company. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.

Dr. Sol J. Barer, Ph.D.

Advisor to the Board of Directors, Rafael Pharmaceuticals

Dr. Sol J. Barer, Chairman of the Board of Teva Pharmaceuticals, Chairman of Centrexion Therapeutics, Lead Director of Contrafect Corp, Chairman of Neximmune, and Board member of 3DBiotherapeutics and Cerecor, Founding Chair of the Hackensack Meridian Center for Discovery and Innovation and advisor to the Israel Biotech Fund. Dr. Barer is a co-founder of Celgene Corporation and served as Celgene’s Executive Chairman, President, CEO, and COO. Previously, he was the founder of the biotechnology group at Celanese Corporation, which was subsequently spun off as Celgene. Dr. Barer is also the founding board member of the Barer Institute, a collaborative cancer drug development initiative of Rafael Holdings, Inc.

Richard Axel, M.D.

Dr. Axel is a molecular neurobiologist and University Professor in the Departments of Neuroscience, Biochemistry and Molecular Biophysics, and of Pathology at Columbia University, an Investigator in the Howard Hughes Medical Institute, and a Co-Director of the Mortimer B. Zuckerman Mind Brain Behavior Institute. In 2004, Dr. Axel won the Nobel Prize in Physiology or Medicine.

Chi Van Dang, M.D., Ph.D.

Chairman of Rafael’s Scientific and Medical Advisory Boards

Director of the Abramson Cancer Center of the University of Pennsylvania. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Dr. Dang currently serves as Rafael’s Chairman of the Scientific and Medical Advisory Boards.

Aaron Drillick

Mr. Drillick is the Chief Financial Officer for Eastern Properties. He is responsible for all financial aspects of the company including financial reporting, construction, and permanent financing. Prior to joining Eastern Properties, Mr. Drillick was a manager at the Federal Reserve Bank of New York, responsible for the Bank’s capital and operating budgets. He has a Bachelors degree from Brooklyn College and a Masters degree from the New York University School of Engineering and Science.

Sanjeev Luther

President, Chief Executive Officer and a member of the board of directors

Sanjeev Luther is credited with significant growth and performance in domestic and international markets. Strategic, pragmatic and results-driven, Sanjeev has led successful business-building and fundraising strategies and increased ROI for both Fortune 500 corporations and startups in pharmaceuticals, biotech, medical devices and diagnostics, including Bristol-Myers Squibb, Novartis, Bausch and Lomb, GE Healthcare and Mallinckrodt. He has a proven track record in driving productivity and reducing costs, with expertise across a range of therapeutic areas and stages, from R&D through commercialization.

Most recently, advancing from CBO to COO to CEO, Sanjeev turned Rafael Pharmaceuticals around from near bankruptcy to its current financial and clinical health. Rafael was an early-stage pharmaceutical company when he joined, and he transformed it into an advanced organization with a robust pipeline in hard-to-treat cancers.

Richard Scheller, Ph.D.

Dr. Scheller is the Chief Science Officer of Google-backed 23andMe. He is the former Head of Genentech Research and Early Development (2009-2014), a member of Genentech’s original scientific team which synthesized Somatostatin, and a former member of the Roche Corporate Executive Committee. Dr. Scheller was previously a professor at Stanford University Medical Center (1982-2001), and an Investigator at the Howard Hughes Medical Institute. In 2013, Dr. Scheller won the Lasker Award.

Robert Shorr, Ph.D., DIC

Chief Scientist and Co-founder

Dr. Shorr has a 40-year track record in drug discovery from concept through approval and market launch. As Rafael’s Chief Scientific Officer, Dr. Shorr’s primary focus is on the discovery and development of safe and effective novel drugs and delivery technology. He has previously served as VP of Science and Technology at Enzon Pharma, VP of Science and Technology and Chief Scientist at United Therapeutics, and Associate Director of Molecular Pharmacology at SmithKline Beecham. At Enzon, Dr. Shorr was responsible for co-development with Schering-Plough of the blockbuster drug, PEG INTRON A, for the treatment of hepatitis and certain forms of melanoma. Dr. Shorr has authored more than 250 technical articles, abstracts, book chapters and conference proceedings and has more than 150 inventions with more than 300 issued and pending patents worldwide. He earned his Ph.D. from the University of London, and a DIC from the University of London Imperial College of Science and Technology.

A. Joseph Stern

Mr. Stern is the Founder and CEO of Eastern Properties, a commercial and residential real estate company located in Cranbury, NJ. He is well known for his commitment and involvement in education as well as other philanthropic causes.

Patrick S. Wilmerding

Mr. Wilmerding is the Co-Founder of Althea Partners LLC, which consults with and invests in early stage companies. Althea Partners led the Series B-4 preferred investment round in Rafael (known as Cornerstone Pharmaceuticals, Inc. at the time). Prior to co-founding Althea Partners, Mr. Wilmerding was a Co-Founder and Director of the Narragansett Bay and Pawtucket Insurance Companies. He also currently serves as a Director of Irresistible Materials Ltd., a next generation nano materials company.